Top Markets
#1 Islamic Coin Islamic Coin +151.56%
#2 Black Phoenix Black Phoenix +35.83%
#3 Palladium Network Palladium Network +20.31%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.14%
#5 Akedo Akedo +16.13%
#6 Fake World Assets Fake World Assets +12.92%
#7 OpenEden OpenEden +12.68%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.64%
#9 clBTC clBTC +12.01%
#10 Arowana Arowana +11.93%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Rang in Aktien #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Aktienkurs
$0.00366968
Zuletzt synchronisiert: 2024-07-23
Marktkapitalisierung
$291.42K
Veränderung (1 Tag)
-0.81%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Bioasis Technologies Inc. (BTI)

Kategorie

Healthcare
Dividendenrendite-Verlauf für Bioasis Technologies Inc. (BTI)
Dividendenrendite (TTM) von Bioasis Technologies Inc. (Aktienkürzel: BTI) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Bioasis Technologies Inc. (BTI) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.65%
BE